MEDICATION GUIDES · BUPROPION
Bupropion
Bupropion — sold as Wellbutrin, and as Zyban when it is prescribed to help someone stop smoking — is an antidepressant that works on dopamine and norepinephrine instead of serotonin. This profile covers what it is, how it works, what the first weeks commonly feel like, the forms it comes in, the seizure warning stated plainly, and the conversations worth having with the prescriber along the way.
This profile describes bupropion in general terms, not a prediction for one person. Benefits, side effects, interactions, and tapering needs vary by dose, health history, and other treatments. Never start, stop, or change a psychiatric medication without the prescribing clinician.
EVIDENCE REVIEW
NOVEMBER 6, 2026
What bupropion is
Bupropion belongs to the aminoketone class and works as an NDRI — a norepinephrine–dopamine reuptake inhibitor. It is chemically unrelated to the SSRIs and to the older tricyclic antidepressants, and among antidepressants in common use it is essentially a class of one: the only widely prescribed antidepressant that leaves serotonin alone. It was first approved in the United States in 1985 and has been in continuous use, in several forms, ever since. In recent U.S. prescription data, it is the second most prescribed antidepressant in the country.
Its labeled uses are narrower than sertraline's: major depressive disorder, and the prevention of seasonal major depressive episodes in seasonal affective disorder. The identical molecule is also sold as Zyban, an aid to smoking cessation — same drug, different name, different job on paper. Prescribers also reach for it in situations the label does not name, most often alongside an SSRI, a pairing covered below. Which of those roles fits a particular person is an individual decision — but the narrow label is worth knowing, because much of what people read about bupropion online concerns uses it was never formally approved for.
How it works — and why it takes weeks
Brain cells signal with several chemical messengers. Serotonin is the one most antidepressants act on. Bupropion acts on two others: norepinephrine, involved in alertness and energy, and dopamine, involved in motivation, drive, and reward. It blocks the pumps — the transporters — that normally pull those two messengers back into the cell that released them, so each signal lasts longer. It does not meaningfully block the serotonin pump, does not work by raising serotonin, and is not a stimulant in the way amphetamine medicines are.
As with the SSRIs, the chemical step happens quickly and the relief does not. The brain recalibrates over weeks — receptors adjust, circuits rebalance — and prescribers generally allow at least four weeks, often six, before judging what a dose can do. Bupropion's own half-life is about 21 hours, but the body converts it into active by-products that last considerably longer, so blood levels build over the first week or so of steady dosing. Energy, focus, and appetite sometimes shift before mood does; early movement there is common, and it is not yet the verdict.
The first weeks, week by week
No two starts are identical, but prescribers hear a recognizable pattern. What follows is what people commonly report — not a schedule anyone is promised.
- Week 1: the activating effects arrive before the antidepressant ones. Insomnia is the most common complaint — which is why the once-daily form is taken in the morning — along with dry mouth, headache, a wired or jittery feeling, and a smaller appetite. Mood usually has not moved yet, and that is expected.
- Week 2: the body's reaction often begins to settle into a routine. Sleep may still run light. Energy and focus are frequently the first things to improve, sometimes noticeably before mood does, and for people also quitting smoking, nicotine cravings may begin to ease.
- Weeks 3–4: the fairer test begins. Steadier mood and motivation become more common, though progress is usually uneven — better days interrupted by ordinary bad ones. This is the typical window for a first check-in with the prescriber, and the point at which the dose may be raised if the response is partial and the side effects allow.
- Weeks 6–8: the full assessment. If little has changed by six to eight weeks at a dose the person can tolerate, that is information for the prescriber — about dose, diagnosis, or choice of medication — not a personal failure.
One molecule, several forms — and why doses are adjusted
Bupropion comes in three rhythms. The original immediate-release form (IR) is taken two or three times a day. The sustained-release form (SR) is taken twice a day, with doses at least eight hours apart. The extended-release form (XL) — the most common today — is taken once a day, in the morning. Zyban is the SR form under its smoking-cessation name, usually taken for a defined course of seven to twelve weeks, with a quit date typically set about a week or two after starting. A fourth product, Aplenzin, is the same active drug carried in a different salt.
The numbers differ by form, which is why the form matters as much as the milligrams. For depression, XL typically starts at 150 mg once daily and moves to a target of 300 mg; the labeled ceiling is 450 mg a day for the extended-release form and 400 mg for the sustained-release form, and single doses carry their own caps — 150 mg for IR, 200 mg for SR. Extended-release tablets must be swallowed whole, never crushed, split, or chewed: breaking the coating defeats the slow release and delivers the dose at once, which raises the seizure risk described next.
Dose increases with bupropion are deliberately gradual — the label instructs prescribers to raise the dose slowly, specifically to keep seizure risk low. An adjustment is not an admission that the first plan failed; it is the medication being fitted to the person. Never adjust the dose on your own, in either direction, and never take an extra dose to make up for a missed one.
The seizure warning — stated plainly
This is the section to read without skimming. Bupropion can cause seizures, and the risk rises with the dose. In the studies behind the label, seizures occurred in roughly 1 in 1,000 people at doses below 300 mg a day, and about 4 in 1,000 at doses up to 450 mg a day. Above the labeled ceiling the risk climbs steeply — which is why the maximum doses and single-dose caps exist, why the tablets are swallowed whole, and why dose increases are gradual.
Some people should not take bupropion at all. It is contraindicated — the label's strongest word — for anyone with a seizure disorder, and for anyone with a current or past diagnosis of anorexia nervosa or bulimia. In the drug's early years, seizures clustered in patients with bulimia taking higher doses, and bupropion was briefly withdrawn from the market in 1986 before returning in 1989 with stricter dose limits. It is also contraindicated for people abruptly stopping alcohol, benzodiazepines, barbiturates, or seizure medicines, because that withdrawal state itself lowers the seizure threshold. The eating-disorder rule is not a technicality, and it is not about weight: if there is any history of an eating disorder, it belongs in the open before the first dose, not after.
Risk also rises when bupropion is combined with other things that lower the seizure threshold — certain other medicines, heavy alcohol use, stimulant misuse among them — and when doses are taken too close together. None of this makes bupropion an unusually dangerous medicine at labeled doses; it makes it a medicine whose rules are the safety system. Respecting the dose, the spacing, and the contraindications is most of the story.
Energy, appetite, and the honest weight data
Ask around about bupropion and weight comes up within a sentence. Here is what the evidence actually says, stated as data rather than as a promise. Bupropion's mechanism tends to reduce appetite modestly — "anorexia" appears in the label's list of common effects, meaning reduced appetite, not the eating disorder. In the trials behind the original label, weight loss of more than five pounds occurred in about 28% of people taking bupropion, compared with about 9% of people taking placebo. Averaged out, that is a modest loss — a few pounds over months, not a transformation — and the averages hide wide variation: many people's weight does not change at all, and some people gain.
Two honest caveats. First, bupropion is not a weight-loss drug: it is not approved as one, and prescribing it to chase the scale would invert its purpose. (A separate combination product pairs it with naltrexone for weight management — a different medicine, with its own label and its own rules.) Second, a shrinking appetite in someone recovering from depression is not automatically good news: eating less can be a symptom returning just as easily as a side effect arriving. Either way it is worth reporting — which is the same advice as everywhere else on this page.
Sex — the side effect that usually isn't
The most common reason prescribers choose bupropion — and the reason many patients ask for it by name — is what it usually does not do. The sexual side effects that commonly accompany serotonin medicines, such as lowered desire and delayed or absent orgasm, are uncommon with bupropion. In the trials behind its label, sexual problems were reported at rates close to placebo, and in studies that compared it directly with SSRIs, bupropion consistently showed less sexual dysfunction.
That difference is a statement about averages, not a guarantee for any one person — desire answers to mood, health, relationships, and a dozen other medicines besides. But when an SSRI is helping everything except a patient's sex life, bupropion is one of the standard conversations: as a switch, or, as the next section describes, as a partner. It starts, as these conversations always do, with the subject being raised out loud.
Why it's paired with SSRIs — and what the pairing requires
Bupropion is frequently prescribed alongside an SSRI such as sertraline, and the logic is the mechanism: the SSRI works the serotonin side, bupropion works the energy-and-motivation side, and the two profiles interlock. Prescribers reach for the pairing when depression has answered only partly, when fatigue and flatness dominate what remains, or when an SSRI's sexual side effects need a counterweight. "Partly" is doing real work in that sentence: adding a second medicine is a response to a partial result, not a judgment that the first one failed.
The pairing carries homework, though. Bupropion blocks a liver enzyme called CYP2D6, which the body uses to clear many other medicines — including several SSRIs, other antidepressants, some antipsychotics, and some heart medicines. Adding bupropion can therefore raise the blood levels of the medicines it sits beside, sometimes substantially, and adjusting the partner drug's dose is often part of the plan. Other medicines push the other way: a group cleared through the enzyme CYP2B6 — certain seizure medicines and HIV medicines among them — can lower bupropion's levels. And one practical footnote almost nobody is warned about: bupropion can cause false-positive results for amphetamines on urine drug screens, worth knowing before a workplace or clinical test, and easily explained with the prescription record.
None of this makes the pairing unusual — it is one of the most common combinations in psychiatry. It makes the full medication list — prescriptions, over-the-counter products, and supplements alike — a real part of the prescription.
Stopping — taper, and the Zyban course
Bupropion has a gentler exit reputation than the serotonin medicines: it is not known for the discontinuation syndrome — the "brain zaps" and flu-like days — that stopping an SSRI abruptly can bring. Gentler is not the same as abrupt-is-fine. The extended-release label instructs a taper: when stopping the 300 mg dose, step down to 150 mg once daily before discontinuing. Changes in activation chemistry can still bring a few unsettled days — irritability, restless sleep — and a return of symptoms is easier to read against a gradual change than a sudden one.
Zyban is the exception that proves the planning rule: the smoking-cessation course is designed to end, usually after seven to twelve weeks, sometimes extended while a quit is still young. Depression treatment carries no such built-in finish line; how long it continues is a recurring conversation with the prescriber, reassessed periodically, as the label puts it. Either way, the ending is planned with the prescriber — not improvised alone.
When to call your doctor promptly
Most side effects are nuisances to report at the next visit. Some things should not wait:
- A seizure — call emergency services (911 in the US). This is the one emergency this medicine specifically carries; afterward, the prescriber needs to know the same day, and the medicine is ordinarily stopped.
- Worsening mood, new agitation, or unusual changes in behavior — especially in the first weeks of treatment or after a dose increase. Contact the prescriber promptly rather than waiting it out.
- Children, teenagers, and young adults need particular watching early on: antidepressant labels carry a boxed warning about increased suicidal thinking and behavior in younger patients in short-term studies. Families should know this before the first dose, not after.
- Thoughts of suicide, at any age: treat it as urgent. In the US, call or text 988, the Suicide and Crisis Lifeline, any time — or go to an emergency department.
- Signs of an allergic reaction — a rash together with swelling of the lips, tongue, or face, or trouble breathing. This needs emergency care.
- A racing or pounding heartbeat, or a sharp rise in blood pressure readings: bupropion can raise blood pressure, and the label advises measuring it before treatment starts and periodically during it.
- New medicines and substances: bupropion must never be combined with an MAOI antidepressant, and a gap of about two weeks is required when switching between the two. Be honest about alcohol, too — heavy drinking, and especially stopping suddenly, both change this medicine's risk picture.
Myth vs reality
Myth: bupropion is basically a stimulant — legal speed on a prescription pad — or, in the other telling, a weight-loss drug wearing an antidepressant costume. Both versions travel well online, because each contains exactly one true ingredient: it is activating, and it does tend to reduce appetite.
Reality: it is neither. Bupropion does not produce the euphoria, craving, or compulsive use that define stimulant misuse, and it is not classified as a controlled substance; its activation is the ordinary consequence of working on norepinephrine and dopamine — the motivation and energy circuits — instead of serotonin. And its weight profile is a side effect of that mechanism, not its purpose: it was approved as an antidepressant in 1985 and remains one. At its best, it is the antidepressant for the depression that looks like exhaustion — no drive, no energy, no spark — prescribed for the symptoms, with the scale left to do whatever it does.
